Endogenous / BiologyEndogenousHuman-supportedUpdated 2026-04-24

Peptide reference file

Orexin-A

Trending #29 in Endogenous8.4k searches/moProven

Orexin-A is an endogenous neuropeptide involved in wakefulness, arousal, feeding behavior, and neuroendocrine regulation.

Current readout: human-supported evidence, endogenous status, endogenous approval state, human evidence appears in the current trail, registered trials are linked, and 3 linked sources in the seed trail.

PubChem CID 56842143 | 2340 PubMed results | 71 trial records | 0 DailyMed labels | 0 Drugs@FDA applications

Orexin-A is mostly discussed because it matters because peptide biology reaches deeply into sleep and arousal systems, not just metabolism and muscle.

The public claim is straightforward: It matters because peptide biology reaches deeply into sleep and arousal systems, not just metabolism and muscle. High-confidence neuropeptide biology reference entry.

In plain language, orexin-A is an endogenous neuropeptide involved in wakefulness, arousal, feeding behavior, and neuroendocrine regulation.

Human-supportedEndogenous
WakefulnessAppetiteNeuropeptide

Aliases: Hypocretin-1

SpecimenOrexin-A specimen
CCCCHHHHHHHNOS
Formula
C152H243N47O44S4
Mass
3561.1
Evidence
Human-supported
Elements
5

Most commonly discussed in relation to Wakefulness, Appetite, Neuropeptide.

What Orexin-A is

Orexin-A is an endogenous neuropeptide involved in wakefulness, arousal, feeding behavior, and neuroendocrine regulation.

Orexin-A is grouped under Endogenous / Biology on PeptideFactCheck because it matters because peptide biology reaches deeply into sleep and arousal systems, not just metabolism and muscle.

The useful starting point is to separate the molecule itself from the internet story around it. It matters because peptide biology reaches deeply into sleep and arousal systems, not just metabolism and muscle.

Why people keep looking it up

It matters because peptide biology reaches deeply into sleep and arousal systems, not just metabolism and muscle.

Orexin-A is an endogenous neuropeptide involved in wakefulness, arousal, feeding behavior, and neuroendocrine regulation.

Orexin-A tends to stay in the conversation because it touches a familiar public theme: wakefulness, appetite, and neuropeptide. That makes it easy for the claim to travel faster than the evidence.

What the evidence can support right now

High-confidence neuropeptide biology reference entry.

Human biology is well established, especially in sleep medicine context.

Mechanistic support across arousal and feeding physiology is extensive.

Why this page carries the current tier: High-confidence neuropeptide biology reference entry.

The current seed trail for Orexin-A is pulling from 2 databases sources and 1 literature source.

Safety, limits, and regulatory context

This is primarily a biology-reference entry, not a straightforward intervention peptide.

Orexin-A is tracked here as endogenous biology.

Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Orexin-A. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.

Molecular and identifier data

The current PubChem match for Orexin-A is CID 56842143. That gives the page a source-backed chemistry record rather than a placeholder identifier block.

PubChem CID
56842143
Formula
C152H243N47O44S4
Molecular weight
3561.1
InChIKey
OFNHNCAUVYOTPM-IIIOAANCSA-N

Matched synonyms include Orexin A, orexin-A, Orexine A, Hypocretin 1, 8RDY08V4VC, 205599-75-3, hypocretin-1, RefChem:928255.

Open PubChem record

Clinical trial snapshot

The current ClinicalTrials.gov intervention query for Orexin-A returns 71 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.

Literature snapshot

The current PubMed query for Orexin-A returns 2340 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.

Source trail

Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.

Safety noteThis content is educational only and does not replace medical advice. Peptide use may carry risks and should be discussed with a qualified medical professional.